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Background
Manic switching during antidepressant treatment has
been reported with every class of antidepressant drugs.
SNRIs, namely venlafaxine, milnacipran and duloxetine
have been increasingly used for the treatment of unipolar
and bipolar depression and are well tolerated and suffi-
ciently effective due to their dual mechanism of action.
Materials and methods
A case of duloxetine-induced hypomania in a non-bipolar
patient is presented, and a brief review of all the cases of
SNRIs' induced mania and hypomania has been carried
out.
Results
A 61-year old female patient was examined as an outpa-
tient, presented with a depressive episode which appeared
during the previous month, despite continuous, prophy-
lactic treatment with sertraline 200 mg/day. According to
her medical records, the patient had a 23-year history of
recurrent depression with severe episodes (ICD-10:F33).
She also had a hyperthymic/cyclothymic temperament
and she occasionally presented with mild paranoid symp-
toms, unrelated to the episodes of depression. Her family
history revealed that two patient's sisters had been institu-
tionalized for unknown severe mental illnesses. Sertraline
was tapered and the patient was switched to duloxetine at
60 mg/day. Three days after initiation of duloxetine, the
patient became irritable, hypertalkative and aggressive
towards her husband. Duloxetine was immediately dis-
continued and the symptoms started to resolve, but remit-
ted completely only after the introduction of quetiapine.
A review of the literature revealed only two reports of
duloxetine-induced mania and a total of 13 reports of
SNRIs-induced mania/hypomania.
Conclusions
The available data suggest that SNRIs, especially venlafax-
ine, can induce mood switching in patients with bipolar
depression and in certain patients with unipolar depres-
sion, but the potential of duloxetine and milnacipran to
induce manic/hypomanic symptoms can not be disre-
garded. Switching appears to be dose-related and treat-
ment initiation with lower doses and upward titration
when needed may be preferable in selected cases and may
help minimizing the risk of mood switching.
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